TMX Group Equity Financing Statistics - December 2021

TMX Group Equity Financing Statistics - December 2021

 
 

   Toronto Stock Exchange, TSX Venture Exchange   

 

 TMX Group today announced its financing activity on Toronto Stock Exchange and TSX Venture Exchange for December 2021 .

 

TSX welcomed nine new issuers in December 2021 , compared with 25 in the previous month and 10 in December 2020 . The new listings were four exchange traded funds, two mining companies, two life sciences companies and one technology company. Total financings raised in December 2021 decreased 52% compared to the previous month, and were down 35% compared to December 2020 . The total number of financings in December 2021 was 56, compared with 60 the previous month and 53 in December 2020 .

 

For additional data relating to the number of transactions billed for TSX, please click on the following link: https://www.tmx.com/resource/en/440  

 

 TSXV welcomed 14 new issuers in December 2021 , compared with 16 in the previous month and eight in December 2020 . The new listings were 11 capital pool companies and three mining companies. Total financings raised in December 2021 increased 2% compared to the previous month, but were down 5% compared to December 2020 . There were 165 financings in December 2021 , compared with 138 in the previous month and 177 in December 2020 .

 

TMX Group consolidated trading statistics for December 2021 can be viewed at www.tmx.com .

 

   Toronto Stock Exchange   

 
 
                                                
 
 

   December 2021   

 
 

   November 2021   

 
 

   December 2020   

 
 

  Issuers Listed  

 
 

  1,749  

 
 

  1,751  

 
 

  1,642  

 
 

  New Issuers Listed  

 
 

  9  

 
 

  25  

 
 

  10  

 
 

  IPOs  

 
 

  5  

 
 

  21  

 
 

  8  

 
 

  Graduates from TSXV  

 
 

  4  

 
 

  3  

 
 

  2  

 
 

  Issues Listed  

 
 

  2,425  

 
 

  2,423  

 
 

  2,293  

 
 

  IPO Financings Raised  

 
 

  $67,250,050  

 
 

  $2,328,258,567  

 
 

  $339,028,246  

 
 

  Secondary Financings Raised  

 
 

  $1,247,278,543  

 
 

  $2,479,445,842  

 
 

  $3,479,516,201  

 
 

  Supplemental Financings Raised  

 
 

  $1,190,475,684  

 
 

  $436,147,496  

 
 

  $47,308,800  

 
 

  Total Financings Raised  

 
 

  $2,505,004,277  

 
 

  $5,243,851,905  

 
 

  $3,865,853,247  

 
 

  Total Number of Financings  

 
 

  56  

 
 

  60  

 
 

  53  

 
 

  Market Cap Listed Issues  

 
 

  $4,223,871,393,563  

 
 

  $4,098,383,716,196  

 
 

  $3,398,550,102,622  

 
 
 

   Year-to-date Statistics   

 
 
                                        
 
 

   2021   

 
 

   2020   

 
 

   % change   

 
 

  New Issuers Listed  

 
 

  213  

 
 

  170  

 
 

  +25.3  

 
 

  IPOs  

 
 

  157  

 
 

  140  

 
 

  +12.1  

 
 

  Graduates from TSXV  

 
 

  36  

 
 

  20  

 
 

  +80.0  

 
 

  IPO Financings Raised  

 
 

  $10,487,796,183  

 
 

  $6,759,887,738  

 
 

  +55.1  

 
 

  Secondary Financings Raised  

 
 

  $28,374,208,875  

 
 

  $27,199,147,749  

 
 

  +4.3  

 
 

  Supplemental Financings Raised  

 
 

  $7,054,778,977  

 
 

  $2,220,900,538  

 
 

  +217.7  

 
 

  Total Financings Raised  

 
 

  $45,916,784,035  

 
 

  $36,179,936,025  

 
 

  +26.9  

 
 

  Total Number of Financings  

 
 

  641  

 
 

  533  

 
 

  +20.3  

 
 

  Market Cap Listed Issues  

 
 

  $4,223,871,393,563  

 
 

  $3,398,550,102,622  

 
 

  +24.3  

 
 
 

   TSX Venture Exchange    **  

 
 
                                                
 
 

   December 2021   

 
 

   November 2021   

 
 

   December 2020   

 
 

  Issuers Listed  

 
 

  1,892  

 
 

  1,899  

 
 

  1,889  

 
 

  New Issuers Listed  

 
 

  14  

 
 

  16  

 
 

  8  

 
 

  IPOs  

 
 

  13  

 
 

  9  

 
 

  5  

 
 

  Graduates to TSX  

 
 

  4  

 
 

  3  

 
 

  2  

 
 

  Issues Listed  

 
 

  2,000  

 
 

  2,011  

 
 

  1,974  

 
 

  IPO Financings Raised  

 
 

  $10,012,922  

 
 

  $70,656,617  

 
 

  $12,042,642  

 
 

  Secondary Financings Raised (1)  

 
 

  $235,851,660  

 
 

  $177,743,941  

 
 

  $370,556,898  

 
 

  Supplemental Financings Raised  

 
 

  $665,389,223  

 
 

  $644,211,413  

 
 

  $576,022,238  

 
 

  Total Financings Raised  

 
 

  $911,253,805  

 
 

  $892,611,971  

 
 

  $958,621,778  

 
 

  Total Number of Financings  

 
 

  165  

 
 

  138  

 
 

  177  

 
 

  Market Cap Listed Issues  

 
 

  $102,467,123,398  

 
 

  $101,455,114,372*  

 
 

  $78,362,951,154  

 
 
 

   Year-to-date Statistics   

 
 
                                        
 
 

   2021   

 
 

   2020   

 
 

   % Change   

 
 

  New Issuers Listed  

 
 

  147  

 
 

  63  

 
 

  +133.3  

 
 

  IPOs  

 
 

  101  

 
 

  39  

 
 

  +159.0  

 
 

  Graduates to TSX  

 
 

  36  

 
 

  20  

 
 

  +80.0  

 
 

  IPO Financings Raised  

 
 

  $269,665,407  

 
 

  $213,018,283  

 
 

  +26.6  

 
 

  Secondary Financings Raised (1)  

 
 

  $3,621,917,540  

 
 

  $1,879,583,265  

 
 

  +92.7  

 
 

  Supplemental Financings Raised  

 
 

  $7,138,371,483  

 
 

  $4,570,886,951  

 
 

  +56.2  

 
 

  Total Financings Raised  

 
 

  $11,029,954,430  

 
 

  $6,663,488,499  

 
 

  +65.5  

 
 

  Total Number of Financings  

 
 

  1,684  

 
 

  1,717  

 
 

  -1.9  

 
 

  Market Cap Listed Issues  

 
 

  $102,467,123,398  

 
 

  $78,362,951,154  

 
 

  +30.8  

 
 
 
 
      
 
 

  *correction  

 
 
 

  **Includes NEX (not applicable to New Issuers Listed, IPOs and IPO Financings Raised)  

 
 
 

  (1)      Secondary financings include prospectus offerings on both a  treasury and secondary basis  

 
 
 

TMX Group does not guarantee either the completeness or the accuracy of this information. The information contained in this media release is provided for informational purposes only and you agree not to rely upon the information contained in this media release for any trading, business, or financial purposes.  By using this media release, you expressly agree to the condition that TMX Group assumes no liability or responsibility for any errors or inaccuracies in this media release.

 

TMX Group welcomes the following companies that listed during December 2021 :

 

   Toronto Stock Exchange   

 
 
                    
 

   Issuer Name   

 
 

   Company Symbol   

 
 

  Aclara Resources Inc.  

 
 

  ARA  

 
 

  BMO Money Market Fund  

 
 

  ZMMK  

 
 

  BriaCell Therapeutics Corp.  

 
 

  BCT  

 
 

  Fidelity Advantage Bitcoin ETF  

 
 

  FBTC & FBTC.U  

 
 

  Givex Information Technology Group Limited  

 
 

  GIVX  

 
 

  Horizons GX Cybersecurity Index ETF  

 
 

  HBUG  

 
 

  Horizons GX Telemedicine and Digital Health Index ETF  

 
 

  HDOC  

 
 

  Numinus Wellness Inc.  

 
 

  NUMI  

 
 

  Orezone Gold Corporation  

 
 

  ORE  

 
 
 

   TSX Venture Exchange   

 
 
                              
 

   Issuer Name   

 
 

   Company Symbol   

 
 

  ECC Ventures 5 Corp.  

 
 

  ECCV.P  

 
 

  ECC Ventures 6 Corp.  

 
 

  ECCS.P  

 
 

  EV Nickel Inc.  

 
 

  EVNI  

 
 

  Fairplay Ventures Inc.  

 
 

  FPY.P  

 
 

  Fountainhall Capital Corp.  

 
 

  FUN.P  

 
 

  Gold Basin Resources Corporation  

 
 

  GXX  

 
 

  Harmony Acquisitions Corp.  

 
 

  MONY.P  

 
 

  New Media Capital 2.0 Inc.  

 
 

  NEME.P  

 
 

  PC 1 CORP.  

 
 

  PCAA.P  

 
 

  Roshni Capital Inc.  

 
 

  ROSH.P  

 
 

  Rumbu Holdings Ltd.  

 
 

  RMB.P  

 
 

  Rupert's Crossing Capital Inc.  

 
 

  RUCC.P  

 
 

  Taura Gold Inc.  

 
 

  TORA  

 
 

  Wittering Capital Corp.  

 
 

  WITT.P  

 
 
 

   About TMX Group (TSX:X)   

 

TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include     Toronto Stock Exchange   ,   TSX Venture Exchange   ,   TSX Alpha Exchange   ,   The Canadian Depository for Securities   ,   Montréal Exchange   ,   Canadian Derivatives Clearing Corporation   , and     Trayport   which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary , Vancouver and New York ), as well as in key international markets including London and Singapore . For more information about TMX Group, visit our website at   www.tmx.com   . Follow TMX Group on Twitter:   @TMXGroup   .

 

SOURCE TMX Group Limited

 

 

 

 Cision View original content: https://www.newswire.ca/en/releases/archive/January2022/11/c2893.html  

 
 

News Provided by Canada Newswire via QuoteMedia

BCT:CA
The Conversation (0)
BriaCell Partners with New York Cancer & Blood Specialists  for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

 

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.

 

"Cancer is complex. It takes a village to care for a cancer patient. At NYCBS, our mission is to offer cancer patients access to state-of-the-art treatments close to their homes, families, and support networks at convenient locations across Long Island, New York City, and Upstate New York," stated Dr. Jeffrey Vacirca, CEO of NYCBS. "We were impressed with the survival data of the Bria-IMT™ regimen to date and look forward to working with the BriaCell team to make these novel therapeutics available to our patients."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

 
  •    The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either     Bria-IMT™ combination or physician's choice therapy (1:1)   
  •  
  •    Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT™   
  •  
  •    The study's primary endpoint is overall survival in patients treated with the Bria-IMT™ combination regimen versus those treated with physician's choice   
  •  
  •    The study initiation follows FDA Fast Track designation and earlier supportive Phase 2 safety and efficacy data in the same patient population   
  •  

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that its registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is fully approved by the Institutional Review Board (IRB) and will soon enroll patients with advanced metastatic breast cancer.

 

"Timely initiation of our pivotal study is a key milestone for us further confirming our expedited timeline for FDA approval of our immunotherapy," stated Dr. William V. Williams, BriaCell's President and CEO. "Based on our recently announced benchmark beating survival data, we strongly believe that our novel immunotherapy may transform the way we treat advanced metastatic breast cancer patients, and we look forward to sharing additional development milestones in the coming months."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

 
  •    Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)   
  •  
  •    21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen   
  •  
  •    No dose limiting toxicities to date   
  •  

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

 

"The promising survival data of BriaCell's combination regimen suggests the potential for an industry-shaping leap in advanced metastatic breast cancer treatment," stated Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate Professor of Clinical Medicine, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ plus check point inhibitors study. "The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pre-treated patient population."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

 

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that the Company has closed the previously announced plan of arrangement spinout transaction (the " Arrangement ") pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the " SpinCo Assets "), were spun-out to BriaPro Therapeutics Corp. (" SpinCo "), resulting in a 23 rd owned subsidiary of the Company with the remaining 13 rd held by BriaCell shareholders (" BriaCell Shareholders ").

 

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

 

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties' plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell's novel immunotherapy, Bria-IMT™, in combination with a check point inhibitor (CPI), in early stage, newly diagnosed, high-risk triple negative breast cancer (TNBC) patients in the neoadjuvant setting.

 

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×